Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention.

Current evidence increasingly supports CYP2C19 genotype-guided P2Y inhibitor selection. Clopidogrel remains the most prescribed P2Y inhibitor despite higher readmission rates than those of more efficacious third-generation P2Y inhibitors. It remains unclear whether pharmacogenetically (PGx)-guided antiplatelet therapy directly reduces readmissions after percutaneous coronary intervention (PCI).